Cord Blood Stem Cells Information

Molecular Medicine News

Sequenom launches iSEQ application softwareFriday, July 4, 2008 @ 5:45AMSequenom, Inc., a leading provider of genetic analysis solutions, announced the launch of the iSEQ application software, a MassARRAY comparative sequence analysis application for automated, high-throughput identification and typing of microbes and viruses, as well as human disease-related molecular markers.

Sigmund appointed to research chairFriday, July 4, 2008 @ 3:26AMCurt D. Sigmund, professor of internal medicine and molecular physiology and biophysics in the University of Iowa Roy J. and Lucille A. Carver College of Medicine, has been named the Roy J. Carver Chair in Hypertension Research. The five-year appointment was effective July 1.

Lackawanna County company hopes to revolutionize vaccine productionFriday, July 4, 2008 @ 3:08AMMAYFIELD — A Lackawanna County company plans to use new federal funding to revolutionize vaccine production so America can better prepare for an avian flu epidemic.

Scientists shed new light into early mechanisms governing cardiovascular specificationThursday, July 3, 2008 @ 6:17PMThe mature heart is composed by different cell types, including contractile cardiac cells, vascular cells, smooth muscle cells as well as pacemaker cells.

Researchers Are First To Simulate The Binding Of Molecules To A ProteinThursday, July 3, 2008 @ 5:21PMYou may not know what it is, but you burn more than your body weight of it every day. Adenosine triphosphate, a tiny molecule that packs a powerful punch, is the primary energy source for most of your cellular functions. Now researchers have identified a key step in the cellular recycling of ATP that allows your body to produce enough of it to survive.

Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. and EuropeThursday, July 3, 2008 @ 4:48PMIntrogen Therapeutics, Inc. (NASDAQ:INGN) today announced a re-allocation of employees to focus on regulatory review and commercial activities. After years of product development, Introgen is directing corporate spending toward regulatory review programs, commercialization and the future marketing of ADVEXIN therapy. Recently the Company achieved the major corporate milestone of filing for ...

Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. and EuropeThursday, July 3, 2008 @ 4:45PMIntrogen Therapeutics, Inc. (NASDAQ:INGN) today announced a re-allocation of employees to focus on regulatory review and commercial activities. After years of product development, Introgen is directing corporate spending toward regulatory ...

Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. and EuropeThursday, July 3, 2008 @ 4:45PMIntrogen Therapeutics, Inc. (7783;NASDAQ:INGN) today announced a re-allocation of employees to focus on

Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. and EuropeThursday, July 3, 2008 @ 4:30PM AUSTIN, Texas----Introgen Therapeutics, Inc. today announced a re-allocation of employees to focus on regulatory review and commercial activities. After years of product development, Introgen is directing corporate spending toward regulatory review programs, commercialization and the future marketing of ADVEXIN therapy.